Radiopharm Theranostics announced second interim data from its U.S. Phase 2b RAD 101 imaging trial in brain metastases, with 90% (18/20) of patients achieving concordance between PET and MRI (primary endpoint) and significant tumor uptake. First five patients show positive trends in sensitivity and specificity, supporting RAD 101's diagnostic potential with final 30-patient data by June 2026.
Key takeaways
90% (18/20) patients dosed with RAD 101 achieved primary endpoint of concordance with MRI
Significant and selective tumor uptake in brain metastases confirmed by images
First five patients with six-month follow-up and/or biopsy data show positive trend for sensitivity and specificity
Final data readout from full 30-patient Phase 2b study expected by June 2026
RAD 101 has FDA Fast Track Designation for distinguishing recurrent brain metastases
Webinar scheduled for March 25, 2026 at 9:00 am AEDT / March 24, 2026 at 6:00 pm EST